CardioTeca CardioTeca CardioTeca CardioTeca
ESPACIO Síndrome coronario agudo

Biblioteca de referencias

Detalles
G
ESPACIO de síndrome coronario agudo › Bloque G › G4

Guías y evidencia

Lo que recomiendan las guías y lo que demuestran los estudios, separando siempre lo aprobado de lo que se investiga.

G4

Todas las fuentes citadas en el ESPACIO, en formato Vancouver, con DOI y PMID verificados, filtrables por tema y descargables para un gestor bibliográfico.

La evidencia en el tiempo: los artículos y guías citados en este ESPACIO, por año (2 anteriores a 1990, fuera del eje)

51015202521112232344641262365482131012814121418202519901995200020052010201520202025
262referencias: 222 artículos y guías, comprobados en PubMed y Crossref, y 40 fichas técnicas63de 2024, 2025 y 202628guías, consensos y declaraciones científicas

La lista se hace sola con lo que citan las páginas de este ESPACIO y se descarga en RIS.

Descargar en RIS (262 referencias)

Artículos y guías en PubMed (219)

  1. Adlam D, Alfonso F, Maas A, Vrints C, Writing Committee. European Society of Cardiology, acute cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection. Eur Heart J. 2018;39(36):3353-3368. doi:10.1093/eurheartj/ehy080 · PMID 29481627H3
  2. Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio AL, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017;38(3):143-153. doi:10.1093/eurheartj/ehw149 · PMID 28158518H3
  3. Alegre O, Formiga F, López-Palop R, Marín F, Vidán MT, Martínez-Sellés M, et al. An Easy Assessment of Frailty at Baseline Independently Predicts Prognosis in Very Elderly Patients With Acute Coronary Syndromes. J Am Med Dir Assoc. 2018;19(4):296-303. doi:10.1016/j.jamda.2017.10.007 · PMID 29153753G3
  4. Alfonso F, Fernández-Pérez C, García-Márquez M, García-Guimaraes M, Bernal JL, Bastante T, et al. Spontaneous coronary artery dissection in Spain: a study using the minimum data set of the Spanish National Health System. Rev Esp Cardiol (Engl Ed). 2022;75(11):903-910. doi:10.1016/j.rec.2022.04.017 · PMID 35716909G3
  5. Alfonso F, Salamanca J, Núñez-Gil I, Del Prado N, Rosillo N, Elola J. Trends in hospital admissions and mortality for tako-tsubo syndrome in Spain. Rev Esp Cardiol (Engl Ed). 2025;78(2):158-160. doi:10.1016/j.rec.2024.08.013 · PMID 39419279G3
  6. Almendro-Delia M, López-Flores L, Uribarri A, Vedia O, Blanco-Ponce E, López-Flores MDC, et al. Recovery of Left Ventricular Function and Long-Term Outcomes in Patients With Takotsubo Syndrome. J Am Coll Cardiol. 2024;84(13):1163-1174. doi:10.1016/j.jacc.2024.05.075 · PMID 39293882G3
  7. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-59. doi:10.1056/NEJMoa061894 · PMID 16899775I1
  8. Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307(3):265-74. doi:10.1001/jama.2011.2002 · PMID 22253393I1
  9. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International Expert Consensus on Switching Platelet P2Y(12) Receptor-Inhibiting Therapies. Circulation. 2017;136(20):1955-1975. doi:10.1161/CIRCULATIONAHA.117.031164 · PMID 29084738C4
  10. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60. doi:10.1016/S0140-6736(09)60503-1 · PMID 19482214I1
  11. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. 1999;100(15):1602-8. doi:10.1161/01.cir.100.15.1602 · PMID 10517730I1
  12. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110(5):588-636. doi:10.1161/01.CIR.0000134791.68010.FA · PMID 15289388D4I1
  13. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354(14):1477-88. doi:10.1056/NEJMoa060898 · PMID 16537665C5G2I1
  14. Armillotta M, Angeli F, Fedele D, Amicone S, Canton L, Cavallo D, et al. Causal Endotype-Based Classification of Myocardial Infarction. JAMA Cardiol. 2026;11(10):951-960. doi:10.1001/jamacardio.2026.3794 · PMID 42667602G3
  15. Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368(15):1379-87. doi:10.1056/NEJMoa1301092 · PMID 23473396G2
  16. Arrarte Esteban V, Campuzano Ruiz R, De Pablo Zarzosa C, Fernández Olmo MR, investigators of the AULARC registry. The state of cardiac rehabilitation in Spain. Results of the AULARC registry. Rev Esp Cardiol (Engl Ed). 2024;77(9):796-798. doi:10.1016/j.rec.2024.04.014 · PMID 38844071C2G3H2
  17. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-92. doi:10.1016/S0140-6736(11)60739-3 · PMID 21663949I1
  18. Barrabés JA, Bardají A, Jiménez-Candil J, del Nogal Sáez F, Bodí V, Basterra N, et al. Prognosis and management of acute coronary syndrome in Spain in 2012: the DIOCLES study. Rev Esp Cardiol (Engl Ed). 2015;68(2):98-106. doi:10.1016/j.rec.2014.03.010 · PMID 25623429G3
  19. Bastante T, Arzamendi D, Martín-Moreiras J, Cid Álvarez AB, en representación de la ACI-SEC, Carballo Garrido J, et al. Spanish cardiac catheterization and coronary intervention registry. 33rd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2023). Rev Esp Cardiol (Engl Ed). 2024;77(11):936-946. doi:10.1016/j.rec.2024.07.015 · PMID 39332624G3
  20. Bastante T, Arzamendi D, Martín-Moreiras J, Cid-Álvarez AB, ACI-SEC. Spanish cardiac catheterization and coronary intervention registry. 34(th) official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2024). Rev Esp Cardiol (Engl Ed). 2025;78(11):992-1003. doi:10.1016/j.rec.2025.07.009 · PMID 40914426G3H2
  21. Beltrame JF, Crea F, Kaski JC, Ogawa H, Ong P, Sechtem U, et al. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 2017;38(33):2565-2568. doi:10.1093/eurheartj/ehv351 · PMID 26245334H3
  22. Bernat I, Aminian A, Pancholy S, Mamas M, Gaudino M, Nolan J, et al. Best Practices for the Prevention of Radial Artery Occlusion After Transradial Diagnostic Angiography and Intervention: An International Consensus Paper. JACC Cardiovasc Interv. 2019;12(22):2235-2246. doi:10.1016/j.jcin.2019.07.043 · PMID 31753298D4
  23. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361(24):2330-41. doi:10.1056/NEJMoa0908629 · PMID 19915222I1
  24. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303-13. doi:10.1056/NEJMoa1300815 · PMID 23473369G2I1
  25. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792 · PMID 30415628G2I1
  26. Biscaglia S, Guiducci V, Escaned J, Moreno R, Lanzilotti V, Santarelli A, et al. Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction. N Engl J Med. 2023;389(10):889-898. doi:10.1056/NEJMoa2300468 · PMID 37634150C5G2
  27. Biscaglia S, Erriquez A, Colaiori I, Hakeem A, Mantovani F, Menozzi M, et al. Complete Revascularization Guided by Functional Coronary Angiography in STEMI. N Engl J Med. 2026;395(10):972-982. doi:10.1056/NEJMoa2605373 · PMID 42670979G2
  28. Boeddinghaus J, Bularga A, Taggart C, Wereski R, McDermott M, Thurston AJF, et al. Implications of a new clinical classification of acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2025;14(3):131-141. doi:10.1093/ehjacc/zuaf002 · PMID 39824208H1H5
  29. Bohula EA, Marston NA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, et al. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. N Engl J Med. 2026;394(2):117-127. doi:10.1056/NEJMoa2514428 · PMID 41211925I1
  30. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800. doi:10.1056/NEJMoa1500857 · PMID 25773268G2I1
  31. Busca E, Airoldi C, Bertoncini F, Buratti G, Casarotto R, Gaboardi S, et al. Bed rest duration and complications after transfemoral cardiac catheterization: a network meta-analysis. Eur J Cardiovasc Nurs. 2023;22(5):454-462. doi:10.1093/eurjcn/zvac098 · PMID 36256701D4
  32. Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, et al. Empagliflozin after Acute Myocardial Infarction. N Engl J Med. 2024;390(16):1455-1466. doi:10.1056/NEJMoa2314051 · PMID 38587237G2
  33. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191 · PMID 37622654B4B6C1C2C3C4C5C6C8D1D3D4E3G1H1H3H4I1I2
  34. Bäck M, Wilhelm M, Marcin T, Machado FVC, Sandberg A, Buccheri S, et al. 2026 ESC Guidelines on cardiac rehabilitation. Eur Heart J. 2026;47(39):5631-5729. doi:10.1093/eurheartj/ehag099 · PMID 42661418B4B6C8D1D4G1
  35. Böhm F, Mogensen B, Engstrøm T, Stankovic G, Srdanovic I, Lønborg J, et al. FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction. N Engl J Med. 2024;390(16):1481-1492. doi:10.1056/NEJMoa2314149 · PMID 38587995C5
  36. Camps-Vilaró A, Subirana I, Elosua R, Palomo I, Sanchis J, Tizón-Marcos H, et al. Analysis of myocardial infarction incidence and case-fatality in the last three decades in the province of Girona. Rev Esp Cardiol (Engl Ed). 2024;77(6):450-458. doi:10.1016/j.rec.2023.10.005 · PMID 37981192G3H2
  37. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504. doi:10.1056/NEJMoa040583 · PMID 15007110G2I1
  38. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97. doi:10.1056/NEJMoa1410489 · PMID 26039521G2I1
  39. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387(11):967-977. doi:10.1056/NEJMoa2208275 · PMID 36018037G2I1
  40. Cequier Á, Ariza-Solé A, Elola FJ, Fernández-Pérez C, Bernal JL, Segura JV, et al. Impact on Mortality of Different Network Systems in the Treatment of ST-segment Elevation Acute Myocardial Infarction. The Spanish Experience. Rev Esp Cardiol (Engl Ed). 2017;70(3):155-161. doi:10.1016/j.rec.2016.07.005 · PMID 27600863G3H2
  41. Cequier Á, Bueno H, Macaya C, Bertomeu V, González-Juanatey JR, Íñiguez A, et al. Trends in cardiovascular care in the National Health System in Spain. Data from the RECALCAR project 2011-2020. Rev Esp Cardiol (Engl Ed). 2023;76(7):519-530. doi:10.1016/j.rec.2022.09.017 · PMID 36493955G3H2
  42. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607-21. doi:10.1016/S0140-6736(05)67660-X · PMID 16271642G2I1
  43. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1622-32. doi:10.1016/S0140-6736(05)67661-1 · PMID 16271643G2I1
  44. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337(7):447-52. doi:10.1056/NEJM199708143370702 · PMID 9250846I1
  45. Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38(41):3070-3078. doi:10.1093/eurheartj/ehx175 · PMID 28510646G2
  46. CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363(10):930-42. doi:10.1056/NEJMoa0909475 · PMID 20818903G2I1
  47. d'Entremont MA, Poorthuis MHF, Fiolet ATL, Amarenco P, Boczar KE, Buysschaert I, et al. Colchicine for secondary prevention of vascular events: a meta-analysis of trials. Eur Heart J. 2025;46(26):2564-2575. doi:10.1093/eurheartj/ehaf210 · PMID 40314334I1
  48. Dang QM, Psaltis PJ, Burgess S, Chandrasekhar J, Mukherjee S, Kritharides L, et al. The Australian-New Zealand spontaneous coronary artery dissection cohort study: predictors of major adverse cardiovascular events and recurrence. Eur Heart J. 2025;46(21):2012-2023. doi:10.1093/eurheartj/ehaf097 · PMID 40049585H3
  49. Daniels LB, Mueller C, Giannitsis E, Meex SJR, Buehlmann D, Dilba P, et al. Establishing Reference Values in Healthy Participants for the Cardiac Troponin T High-Sensitivity Gen 6 Assay: REF-TSIX Global Reference Study. Clin Chem. 2026;72(4):488-502. doi:10.1093/clinchem/hvag011 · PMID 41564003G1H4
  50. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385-90. doi:10.1016/s0140-6736(00)04560-8 · PMID 11356434G2I1
  51. De Backer J, Haugaa KH, Hasselberg NE, de Hosson M, Brida M, Castelletti S, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J. 2025;46(43):4462-4568. doi:10.1093/eurheartj/ehaf193 · PMID 40878294C6
  52. de Belder A, Myat A, Blaxill J, Haworth P, O'Kane PD, Hatrick R, et al. Revascularisation or medical therapy in elderly patients with acute anginal syndromes: the RINCAL randomised trial. EuroIntervention. 2021;17(1):67-74. doi:10.4244/EIJ-D-20-00975 · PMID 33226000C5
  53. de Miguel-Yanes JM, Jiménez-García R, Hernandez-Barrera V, de Miguel-Díez J, Muñoz-Rivas N, Méndez-Bailón M, et al. Sex Differences in the Incidence and Outcomes of Acute Myocardial Infarction in Spain, 2016-2018: A Matched-Pair Analysis. J Clin Med. 2021;10(8). doi:10.3390/jcm10081795 · PMID 33924190G3H2
  54. Desch S, Freund A, Akin I, Behnes M, Preusch MR, Zelniker TA, et al. Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation. N Engl J Med. 2021;385(27):2544-2553. doi:10.1056/NEJMoa2101909 · PMID 34459570G2
  55. Diletti R, den Dekker WK, Bennett J, Schotborgh CE, van der Schaaf R, Sabaté M, et al. Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial. Lancet. 2023;401(10383):1172-1182. doi:10.1016/S0140-6736(23)00351-3 · PMID 36889333C5
  56. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342(8875):821-8. PMID 8104270G2I1
  57. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000;355(9219):1936-42. doi:10.1016/S0140-6736(00)02324-2 · PMID 10859038I1
  58. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-1330. doi:10.1056/NEJMoa1709118 · PMID 28844192G2
  59. Erlinge D, Omerovic E, Fröbert O, Linder R, Danielewicz M, Hamid M, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med. 2017;377(12):1132-1142. doi:10.1056/NEJMoa1706443 · PMID 28844201C5G2I1
  60. Estévez-Loureiro R, Calviño-Santos R, Vázquez JM, Barge-Caballero E, Salgado-Fernández J, Piñeiro M, et al. Safety and feasibility of returning patients early to their originating centers after transfer for primary percutaneous coronary intervention. Rev Esp Cardiol. 2009;62(12):1356-64. doi:10.1016/s1885-5857(09)73529-7 · PMID 20038401B6
  61. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292(1):45-54. doi:10.1001/jama.292.1.45 · PMID 15238590C5G2I1
  62. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464-76. doi:10.1056/NEJMoa055443 · PMID 16537663C5G2I1
  63. Fröbert O, Götberg M, Erlinge D, Akhtar Z, Christiansen EH, MacIntyre CR, et al. Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation. 2021;144(18):1476-1484. doi:10.1161/CIRCULATIONAHA.121.057042 · PMID 34459211G2
  64. FUTURA/OASIS-8 Trial Group, Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA. 2010;304(12):1339-49. doi:10.1001/jama.2010.1320 · PMID 20805623G2I1
  65. Gaba P, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, et al. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. J Am Coll Cardiol. 2022;79(17):1660-1671. doi:10.1016/j.jacc.2022.02.035 · PMID 35483753I1
  66. García-Guimaraes M, Bastante T, Macaya F, Roura G, Sanz R, Barahona Alvarado JC, et al. Spontaneous coronary artery dissection in Spain: clinical and angiographic characteristics, management, and in-hospital events. Rev Esp Cardiol (Engl Ed). 2021;74(1):15-23. doi:10.1016/j.rec.2020.04.002 · PMID 32418854G3
  67. Ge Z, Kan J, Gao X, Raza A, Zhang JJ, Mohydin BS, et al. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Lancet. 2024;403(10439):1866-1878. doi:10.1016/S0140-6736(24)00473-2 · PMID 38599220G2I1
  68. Gencer B, Mach F, Murphy SA, De Ferrari GM, Huber K, Lewis BS, et al. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. JAMA Cardiol. 2020;5(8):952-957. doi:10.1001/jamacardio.2020.0882 · PMID 32432684I1
  69. Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur Heart J. 2018;39(22):2032-2046. doi:10.1093/eurheartj/ehy076 · PMID 29850871H3
  70. Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. Eur Heart J. 2018;39(22):2047-2062. doi:10.1093/eurheartj/ehy077 · PMID 29850820H3
  71. Gibson CM, Steg PG, Bahit MC, Al-Lamee R, Mehta SR, Mehran R, et al. Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event. N Engl J Med. 2026;395(16):1575-1584. doi:10.1056/NEJMoa2608717 · PMID 42670965G2
  72. Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet. 2020;395(10233):1374-1381. doi:10.1016/S0140-6736(20)30325-1 · PMID 32334703C5G2I1
  73. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 1994;343(8906):1115-22. PMID 7910229G2I1
  74. Grines CL, Marsalese DL, Brodie B, Griffin J, Donohue B, Costantini CR, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction. J Am Coll Cardiol. 1998;31(5):967-72. doi:10.1016/s0735-1097(98)00031-x · PMID 9561995B6
  75. Guimarães PO, Franken M, Tavares CAM, Antunes MO, Silveira FS, Andrade PB, et al. Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. N Engl J Med. 2025;393(21):2095-2106. doi:10.1056/NEJMoa2507980 · PMID 40888723G2
  76. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet. 1997;349(9064):1493-7. doi:10.1016/s0140-6736(97)04442-5 · PMID 9167457I1
  77. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826-3924. doi:10.1093/eurheartj/ehac270 · PMID 36017553C4C6
  78. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361(24):2318-29. doi:10.1056/NEJMoa0908628 · PMID 19915221I1
  79. Hayes SN, Kim ESH, Saw J, Adlam D, Arslanian-Engoren C, Economy KE, et al. Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement From the American Heart Association. Circulation. 2018;137(19):e523-e557. doi:10.1161/CIR.0000000000000564 · PMID 29472380H3
  80. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-53. doi:10.1056/NEJM200001203420301 · PMID 10639539I1
  81. Henrikson CA, Howell EE, Bush DE, Miles JS, Meininger GR, Friedlander T, et al. Chest pain relief by nitroglycerin does not predict active coronary artery disease. Ann Intern Med. 2003;139(12):979-86. doi:10.7326/0003-4819-139-12-200312160-00007 · PMID 14678917I1
  82. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Málek I, Nyberg G, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981;2(8251):823-7. doi:10.1016/s0140-6736(81)91101-6 · PMID 6116950I1
  83. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. 1999;341(9):625-34. doi:10.1056/NEJM199908263410901 · PMID 10460813G2
  84. Hofmann R, James SK, Jernberg T, Lindahl B, Erlinge D, Witt N, et al. Oxygen Therapy in Suspected Acute Myocardial Infarction. N Engl J Med. 2017;377(13):1240-1249. doi:10.1056/NEJMoa1706222 · PMID 28844200G2
  85. Hong SJ, Lee YJ, Lee SJ, Hong BK, Kang WC, Lee JY, et al. Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial. JAMA. 2023;329(13):1078-1087. doi:10.1001/jama.2023.2487 · PMID 36877807I1
  86. Ibanez B, Macaya C, Sánchez-Brunete V, Pizarro G, Fernández-Friera L, Mateos A, et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation. 2013;128(14):1495-503. doi:10.1161/CIRCULATIONAHA.113.003653 · PMID 24002794G2I1
  87. Ibanez B, Latini R, Rossello X, Dominguez-Rodriguez A, Fernández-Vazquez F, Pelizzoni V, et al. Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. N Engl J Med. 2025;393(19):1889-1900. doi:10.1056/NEJMoa2504735 · PMID 40888702G2H4I1
  88. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation. 1998;97(22):2202-12. doi:10.1161/01.cir.97.22.2202 · PMID 9631869I1
  89. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345(8951):669-85. PMID 7661937G2I1
  90. James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, et al. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evid. 2024;3(2):EVIDoa2300286. doi:10.1056/EVIDoa2300286 · PMID 38320489G2
  91. Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med. 2015;372(15):1389-98. doi:10.1056/NEJMoa1415098 · PMID 25853743G2
  92. Jolly SS, d'Entremont MA, Lee SF, Mian R, Tyrwhitt J, Kedev S, et al. Colchicine in Acute Myocardial Infarction. N Engl J Med. 2025;392(7):633-642. doi:10.1056/NEJMoa2405922 · PMID 39555823G2I1
  93. Jolly SS, d'Entremont MA, Pitt B, Lee SF, Mian R, Tyrwhitt J, et al. Routine Spironolactone in Acute Myocardial Infarction. N Engl J Med. 2025;392(7):643-652. doi:10.1056/NEJMoa2405923 · PMID 39555814G2I1
  94. Jones WS, Mulder H, Wruck LM, Pencina MJ, Kripalani S, Muñoz D, et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med. 2021;384(21):1981-1990. doi:10.1056/NEJMoa2102137 · PMID 33999548I1
  95. Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, et al. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. JAMA. 2020;323(23):2407-2416. doi:10.1001/jama.2020.7580 · PMID 32543684G2I1
  96. Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400(10349):380-390. doi:10.1016/S0140-6736(22)00916-3 · PMID 35863366G2I1
  97. Kim CJ, Park MW, Kim MC, Choo EH, Hwang BH, Lee KY, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021;398(10308):1305-1316. doi:10.1016/S0140-6736(21)01445-8 · PMID 34627490G2
  98. Kim HS, Kang J, Hwang D, Han JK, Yang HM, Kang HJ, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet. 2020;396(10257):1079-1089. doi:10.1016/S0140-6736(20)31791-8 · PMID 32882163G2
  99. Knowlton KU, Navar AM, Anderson JL, Brown AS, Muhlestein JB, Kleeman K, et al. Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial. J Am Heart Assoc. 2026;15(10):e043655. doi:10.1161/JAHA.125.043655 · PMID 42132192G2I1
  100. Koo BK, Kang J, Park KW, Rhee TM, Yang HM, Won KB, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021;397(10293):2487-2496. doi:10.1016/S0140-6736(21)01063-1 · PMID 34010616G2
  101. Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, et al. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452-2462. doi:10.1016/j.jacc.2019.08.010 · PMID 31479722G2I1
  102. Kristensen AMD, Rossello X, Atar D, Yndigegn T, Kimura T, Latini R, et al. Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. N Engl J Med. 2026;394(6):540-550. doi:10.1056/NEJMoa2512686 · PMID 41211954G2H4I1
  103. Kunadian V, Mossop H, Shields C, Bardgett M, Watts P, Teare MD, et al. Invasive Treatment Strategy for Older Patients with Myocardial Infarction. N Engl J Med. 2024;391(18):1673-1684. doi:10.1056/NEJMoa2407791 · PMID 39225274C5G2
  104. Køber L, Adamo M, Ruwald AC, Tomasoni D, Anderson LJ, Andersson C, et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026;47(38):5346-5457. doi:10.1093/eurheartj/ehag100 · PMID 42661420C6I1
  105. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35. doi:10.1056/NEJMoa050461 · PMID 15755765I1
  106. Lee SJ, Lee YJ, Lee K, Cho DK, Cho YH, Ahn SG, et al. Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients. N Engl J Med. 2026;doi: 10.1056/NEJMoa2608533. doi:10.1056/NEJMoa2608533 · PMID 42670964G2
  107. Lee YJ, Hong SJ, Kang WC, Hong BK, Lee JY, Lee JB, et al. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ. 2023;383:e075837. doi:10.1136/bmj-2023-075837 · PMID 37852649G2I1
  108. Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen M, et al. Coronary Angiography after Cardiac Arrest without ST-Segment Elevation. N Engl J Med. 2019;380(15):1397-1407. doi:10.1056/NEJMoa1816897 · PMID 30883057G2
  109. Li Y, Liang Z, Qin L, Wang M, Wang X, Zhang H, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. Lancet. 2022;400(10366):1847-1857. doi:10.1016/S0140-6736(22)01999-7 · PMID 36351459C5G2I1
  110. Liang K, Bisaccia G, Leo I, Williams MGL, Dastidar A, Strange JW, et al. CMR reclassifies the majority of patients with suspected MINOCA and non MINOCA. Eur Heart J Cardiovasc Imaging. 2023;25(1):8-15. doi:10.1093/ehjci/jead182 · PMID 37526288H3
  111. Lim HS, Tycinska A, Delmas C, Moller JE, Pöss J, Stoppe C, et al. Criteria for the diagnosis of cardiogenic shock-European perspective: A Clinical Consensus Statement of the Association for Acute CardioVascular Care, the Heart Failure Association, and the European Association of Percutaneous Cardiovascular Interventions of the ESC. Eur Heart J Acute Cardiovasc Care. 2026;15(8):634-648. doi:10.1093/ehjacc/zuag100 · PMID 42667225C6
  112. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380(16):1509-1524. doi:10.1056/NEJMoa1817083 · PMID 30883055G2
  113. Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-4378. doi:10.1093/eurheartj/ehaf190 · PMID 40878289B4G1I1
  114. Mafham MM, Zayed MG, Collins R, Sabatine MS, Armitage J, Brittain D, et al. HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics. Am Heart J. 2026;303:107546. doi:10.1016/j.ahj.2026.107546 · PMID 42567431I1
  115. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. doi:10.1093/eurheartj/ehad192 · PMID 37622663C6
  116. Mason PJ, Shah B, Tamis-Holland JE, Bittl JA, Cohen MG, Safirstein J, et al. An Update on Radial Artery Access and Best Practices for Transradial Coronary Angiography and Intervention in Acute Coronary Syndrome: A Scientific Statement From the American Heart Association. Circ Cardiovasc Interv. 2018;11(9):e000035. doi:10.1161/HCV.0000000000000035 · PMID 30354598D4
  117. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155-66. doi:10.1056/NEJMoa1409312 · PMID 25399658G2
  118. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9-19. doi:10.1056/NEJMoa1112277 · PMID 22077192G2
  119. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019;381(21):2032-2042. doi:10.1056/NEJMoa1908419 · PMID 31556978G2I1
  120. Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360(21):2165-75. doi:10.1056/NEJMoa0807986 · PMID 19458363G2
  121. Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med. 2019;381(15):1411-1421. doi:10.1056/NEJMoa1907775 · PMID 31475795C5G2
  122. Miguel Gonçalves C, Carvalho M, Vazão A, Cabral M, Martins A, Saraiva F, et al. Sex-related differences in ST-segment elevation myocardial infarction: A Portuguese multicenter national registry analysis. Rev Port Cardiol. 2025;44(3):167-176. doi:10.1016/j.repc.2024.06.005 · PMID 39216527G3
  123. Mileva N, Paolisso P, Gallinoro E, Fabbricatore D, Munhoz D, Bergamaschi L, et al. Diagnostic and Prognostic Role of Cardiac Magnetic Resonance in MINOCA: Systematic Review and Meta-Analysis. JACC Cardiovasc Imaging. 2023;16(3):376-389. doi:10.1016/j.jcmg.2022.12.029 · PMID 36889851H3
  124. Mills NL, Newby LK, Zaman S, Almahmeed WA, Bucciarelli-Ducci C, Colvin MM, et al. Fifth Universal Definition of Myocardial Infarction (2026). Eur Heart J. 2026;47(40):5911-5958. doi:10.1093/eurheartj/ehag101 · PMID 42661425B6C1C5C6C7C8D1D3E3G1H1H3H4
  125. Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet. 2011;378(9792):693-703. doi:10.1016/S0140-6736(11)60876-3 · PMID 21856483C3C5G2I1
  126. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369(11):999-1010. doi:10.1056/NEJMoa1308075 · PMID 23991622G2I1
  127. Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt F, et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. Eur Heart J. 2014;35(34):2295-302. doi:10.1093/eurheartj/ehu164 · PMID 24780614G2I1
  128. Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371(11):1016-27. doi:10.1056/NEJMoa1407024 · PMID 25175921G2
  129. Montalescot G, Ferrari E, Souteyrand G, Bouleti C, Range G, Batias-Moreau L, et al. LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial. JAMA. 2026;doi: 10.1001/jama.2026.17302. doi:10.1001/jama.2026.17302 · PMID 42666092G2I1
  130. Morrone D, Alberti M, Cravo J, Espinosa Pascual MJ, Alonso Martín JJ, Reskovic Luksic V, et al. The DiagnOsis of MINOCA (DOMINO) registry: a real-world use of multimodality imaging and its impact on etiologic classification. Eur J Prev Cardiol. 2026;pii: zwag422. doi: 10.1093/eurjpc/zwag422. doi:10.1093/eurjpc/zwag422 · PMID 42661462G3
  131. Munkhaugen J, Kristensen AMD, Halvorsen S, Holmager T, Olsen MH, Bakken A, et al. Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. N Engl J Med. 2025;393(19):1901-1911. doi:10.1056/NEJMoa2505985 · PMID 40888716G2H4I1
  132. Møller JE, Engstrøm T, Jensen LO, Eiskjær H, Mangner N, Polzin A, et al. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med. 2024;390(15):1382-1393. doi:10.1056/NEJMoa2312572 · PMID 38587239G2
  133. Nadarajah R, Ludman P, Laroche C, Appelman Y, Brugaletta S, Budaj A, et al. Sex-specific presentation, care, and clinical events in individuals admitted with NSTEMI: the ACVC-EAPCI EORP NSTEMI registry of the European Society of Cardiology. Eur Heart J Acute Cardiovasc Care. 2024;13(1):36-45. doi:10.1093/ehjacc/zuad134 · PMID 37926912G3
  134. Naidu SS, Baran DA, Jentzer JC, Hollenberg SM, van Diepen S, Basir MB, et al. SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies: This statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021. J Am Coll Cardiol. 2022;79(9):933-946. doi:10.1016/j.jacc.2022.01.018 · PMID 35115207C6
  135. Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268-2280. doi:10.1001/jama.2020.22258 · PMID 33190147G2I1
  136. Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, et al. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imaging. 2022;15(7):1308-1321. doi:10.1016/j.jcmg.2022.03.002 · PMID 35431172G2I1
  137. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838-1847. doi:10.1056/NEJMoa2021372 · PMID 32865380G2I1
  138. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388(15):1353-1364. doi:10.1056/NEJMoa2215024 · PMID 36876740G2I1
  139. O'Callaghan D, Rai H, Giacoppo D, Coughlan JJ, Colleran R, Durand R, et al. Immediate Versus Staged Complete Revascularization in Multivessel Disease and STEMI: A Meta-Analysis of Randomized Trials. JACC Cardiovasc Interv. 2026;19(19):2589-2600. doi:10.1016/j.jcin.2026.07.033 · PMID 42863871C5
  140. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA. 1996;276(10):811-5. PMID 8769591I1
  141. Omerovic E, Koul S, Andersson J, Pontén J, Björklund F, Kastberg R, et al. Prasugrel versus Ticagrelor in Acute Coronary Syndromes. N Engl J Med. 2026;doi: 10.1056/NEJMoa2609057. doi:10.1056/NEJMoa2609057 · PMID 42670968C5G2
  142. Opstal TSJ, Fiolet ATL, van Broekhoven A, Mosterd A, Eikelboom JW, Nidorf SM, et al. Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. J Am Coll Cardiol. 2021;78(9):859-866. doi:10.1016/j.jacc.2021.06.037 · PMID 34446156I1
  143. Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation. 2015;131(10):861-70. doi:10.1161/CIRCULATIONAHA.114.011201 · PMID 25587100H3
  144. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437-45. doi:10.1001/jama.294.19.2437 · PMID 16287954I1
  145. Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004;292(1):89-96. doi:10.1001/jama.292.1.89 · PMID 15238596I1
  146. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-906. doi:10.1056/NEJMoa032292 · PMID 14610160G2I1
  147. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, et al. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med. 2021;385(20):1845-1855. doi:10.1056/NEJMoa2104508 · PMID 34758252G2I1
  148. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-21. doi:10.1056/NEJMoa030207 · PMID 12668699G2I1
  149. Pizarro G, Fernández-Friera L, Fuster V, Fernández-Jiménez R, García-Ruiz JM, García-Álvarez A, et al. Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). J Am Coll Cardiol. 2014;63(22):2356-62. doi:10.1016/j.jacc.2014.03.014 · PMID 24694530I1
  150. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13. doi:10.1016/S0140-6736(03)13800-7 · PMID 12853193I1
  151. Popovic B, Agrinier N, Bouchahda N, Pinelli S, Maigrat CH, Metzdorf PA, et al. Coronary Embolism Among ST-Segment-Elevation Myocardial Infarction Patients: Mechanisms and Management. Circ Cardiovasc Interv. 2018;11(1):e005587. doi:10.1161/CIRCINTERVENTIONS.117.005587 · PMID 29311288H3
  152. Puymirat E, Cayla G, Cottin Y, Elbaz M, Henry P, Gerbaud E, et al. Twenty-year trends in profile, management and outcomes of patients with ST-segment elevation myocardial infarction according to use of reperfusion therapy: Data from the FAST-MI program 1995-2015. Am Heart J. 2019;214:97-106. doi:10.1016/j.ahj.2019.05.007 · PMID 31181374G3
  153. Puymirat E, Cayla G, Simon T, Steg PG, Montalescot G, Durand-Zaleski I, et al. Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. N Engl J Med. 2021;385(4):297-308. doi:10.1056/NEJMoa2104650 · PMID 33999545G2
  154. Rajwani A, Giudicatti L, Telyuk P, Maredia N, Ihdayhid A, Chieng D, et al. Clinical impact of cardiac magnetic resonance imaging in myocardial infarction with non-obstructive coronary arteries: a prospective multicentre cohort study. Heart. 2025;112(2):95-102. doi:10.1136/heartjnl-2024-325181 · PMID 40514208H3
  155. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2(8607):349-60. PMID 2899772G2I1
  156. Rao SV, O'Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;85(22):2135-2237. doi:10.1016/j.jacc.2024.11.009 · PMID 40013746G1
  157. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387 · PMID 32187462G2I1
  158. Reddy RK, Koeckerling D, Eichhorn C, Jamil Y, Ardissino M, Braun V, et al. Early Invasive or Conservative Strategies for Older Patients With Acute Coronary Syndromes: A Meta-Analysis. JAMA Intern Med. 2025;185(8):966-975. doi:10.1001/jamainternmed.2025.2058 · PMID 40549394C5
  159. Reynolds HR, Maehara A, Kwong RY, Sedlak T, Saw J, Smilowitz NR, et al. Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Underlying Causes of Myocardial Infarction With Nonobstructive Coronary Arteries in Women. Circulation. 2021;143(7):624-640. doi:10.1161/CIRCULATIONAHA.120.052008 · PMID 33191769H3
  160. Ribeiro Carvalho C, Bernardo MC, Martins Moreira I, Mateus P, Baptista A, Moreira I, et al. Timing of coronary angiography in high-risk non-ST-elevation acute coronary syndrome: results from the Portuguese Registry for Acute Coronary Syndromes (ProACS). Coron Artery Dis. 2025;36(2):166-172. doi:10.1097/MCA.0000000000001457 · PMID 39506530G3
  161. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207. doi:10.1056/NEJMoa0807646 · PMID 18997196I1
  162. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914 · PMID 28845751G2
  163. Rizas KD, Mourouzis K, Rath D, Olivier CB, Villegas Sierra LE, Korovesis T, et al. Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial. Nat Med. 2026;doi: 10.1038/s41591-026-04629-7. doi:10.1038/s41591-026-04629-7 · PMID 42668287G2
  164. Rodríguez-Leor O, Cid-Álvarez AB, Pérez de Prado A, Rosselló X, Ojeda S, Serrador A, et al. Analysis of the management of ST-segment elevation myocardial infarction in Spain. Results from the ACI-SEC Infarction Code Registry. Rev Esp Cardiol (Engl Ed). 2022;75(8):669-680. doi:10.1016/j.rec.2021.12.005 · PMID 35067471D1G3H2
  165. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297-309. doi:10.1056/NEJMoa1205512 · PMID 22920930C5G2I1
  166. Roolvink V, Ibáñez B, Ottervanger JP, Pizarro G, van Royen N, Mateos A, et al. Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. J Am Coll Cardiol. 2016;67(23):2705-2715. doi:10.1016/j.jacc.2016.03.522 · PMID 27050189G2I1
  167. Rossello X, Prescott EIB, Kristensen AMD, Latini R, Fuster V, Fagerland MW, et al. β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials. Lancet. 2025;406(10508):1128-1137. doi:10.1016/S0140-6736(25)01592-2 · PMID 40897190G2H4I1
  168. Räber L, Ueki Y, Otsuka T, Losdat S, Häner JD, Lonborg J, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771-1781. doi:10.1001/jama.2022.5218 · PMID 35368058G2I1
  169. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179-89. doi:10.1056/NEJMoa050522 · PMID 15758000G2I1
  170. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664 · PMID 28304224G2I1
  171. Sanchis J, Bueno H, Miñana G, Guerrero C, Martí D, Martínez-Sellés M, et al. Effect of Routine Invasive vs Conservative Strategy in Older Adults With Frailty and Non-ST-Segment Elevation Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA Intern Med. 2023;183(5):407-415. doi:10.1001/jamainternmed.2023.0047 · PMID 36877502C5G2
  172. Savonitto S, Cavallini C, Petronio AS, Murena E, Antonicelli R, Sacco A, et al. Early aggressive versus initially conservative treatment in elderly patients with non-ST-segment elevation acute coronary syndrome: a randomized controlled trial. JACC Cardiovasc Interv. 2012;5(9):906-16. doi:10.1016/j.jcin.2012.06.008 · PMID 22995877C5
  173. Schulz-Menger J, Collini V, Gröschel J, Adler Y, Brucato A, Christian V, et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. Eur Heart J. 2025;46(40):3952-4041. doi:10.1093/eurheartj/ehaf192 · PMID 40878297H3
  174. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711-8. doi:10.1001/jama.285.13.1711 · PMID 11277825G2I1
  175. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107. doi:10.1056/NEJMoa1801174 · PMID 30403574G2I1
  176. Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019;381(16):1524-1534. doi:10.1056/NEJMoa1908973 · PMID 31475799C5G2I1
  177. SEC Working Group for the 2023 ESC guidelines for the management of acute coronary syndromes and SEC Guidelines Committee. Comments on the 2023 ESC guidelines for the management of acute coronary syndromes. Rev Esp Cardiol (Engl Ed). 2024;77(3):201-205. doi:10.1016/j.rec.2023.11.006 · PMID 38008211G1
  178. Seto AH, Shroff A, Abu-Fadel M, Blankenship JC, Boudoulas KD, Cigarroa JE, et al. Length of stay following percutaneous coronary intervention: An expert consensus document update from the society for cardiovascular angiography and interventions. Catheter Cardiovasc Interv. 2018;92(4):717-731. doi:10.1002/ccd.27637 · PMID 29691963B6
  179. Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390(10104):1747-1757. doi:10.1016/S0140-6736(17)32155-4 · PMID 28855078G2I1
  180. Silvain J, Beygui F, Barthélémy O, Pollack C Jr, Cohen M, Zeymer U, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012;344:e553. doi:10.1136/bmj.e553 · PMID 22306479I1
  181. Silvain J, Cayla G, Ferrari E, Range G, Puymirat E, Delarche N, et al. Beta-Blocker Interruption or Continuation after Myocardial Infarction. N Engl J Med. 2024;391(14):1277-1286. doi:10.1056/NEJMoa2404204 · PMID 39213187G2H4I1
  182. Silvain J, Choi KH, Monguillon V, Kang D, Cayla G, Kim W, et al. Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data. Lancet. 2026;408(10560):1093-1102. doi:10.1016/S0140-6736(26)01426-1 · PMID 42669300G2
  183. Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013;382(9909):1981-92. doi:10.1016/S0140-6736(13)61615-3 · PMID 24011551G2I1
  184. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218-30. doi:10.1056/NEJMoa0708191 · PMID 18499566C5G2I1
  185. Stähli BE, Varbella F, Linke A, Schwarz B, Felix SB, Seiffert M, et al. Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med. 2023;389(15):1368-1379. doi:10.1056/NEJMoa2307823 · PMID 37634190C5G2
  186. Szummer K, Wallentin L, Lindhagen L, Alfredsson J, Erlinge D, Held C, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. Eur Heart J. 2017;38(41):3056-3065. doi:10.1093/eurheartj/ehx515 · PMID 29020314G3
  187. Takahashi K, Kozuma K, Morino Y, Kashiwabara K, Otake H, Suwa S, et al. Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI. N Engl J Med. 2026;doi: 10.1056/NEJMoa2606997. doi:10.1056/NEJMoa2606997 · PMID 42670955G2
  188. Tamis-Holland JE, Jneid H, Reynolds HR, Agewall S, Brilakis ES, Brown TM, et al. Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2019;139(18):e891-e908. doi:10.1161/CIR.0000000000000670 · PMID 30913893H3
  189. Tarantini G, Honton B, Paradies V, Lemesle G, Range G, Godin M, et al. Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction. N Engl J Med. 2025;393(21):2083-2094. doi:10.1056/NEJMoa2508808 · PMID 40888726G2
  190. Tarantini G, Zhang X, Nai Fovino L, Kan J, Ge Z, Cayla G, et al. One vs twelve month aspirin after percutaneous coronary intervention for acute myocardial infarction: individual patient-data analysis of TARGET-FIRST and ULTIMATE-DAPT trials. Eur Heart J. 2026;pii: ehag737. doi: 10.1093/eurheartj/ehag737. doi:10.1093/eurheartj/ehag737 · PMID 42667241G2
  191. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497-2505. doi:10.1056/NEJMoa1912388 · PMID 31733140G2I1
  192. Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S, et al. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet. 2016;387(10023):1057-1065. doi:10.1016/S0140-6736(15)01166-6 · PMID 26794722C5
  193. Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, et al. Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med. 2015;373(10):929-38. doi:10.1056/NEJMoa1406761 · PMID 26332547H3
  194. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287-96. doi:10.1056/NEJMoa1208410 · PMID 22920912G2
  195. Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med. 2017;377(25):2419-2432. doi:10.1056/NEJMoa1710261 · PMID 29083953C5G2
  196. Thiele H, Zeymer U, Akin I, Behnes M, Rassaf T, Mahabadi AA, et al. Extracorporeal Life Support in Infarct-Related Cardiogenic Shock. N Engl J Med. 2023;389(14):1286-1297. doi:10.1056/NEJMoa2307227 · PMID 37634145G2
  197. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237-269. doi:10.1093/eurheartj/ehy462 · PMID 30165617G1H1H3
  198. Tian J, Wang Z, Wang Y, Wang F, Peng X, Xiao J, et al. Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease. N Engl J Med. 2026;395(3):233-242. doi:10.1056/NEJMoa2517588 · PMID 42456136G2
  199. Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, et al. Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation. 2020;142(20):1890-1900. doi:10.1161/CIRCULATIONAHA.120.050771 · PMID 32862667I1
  200. Valgimigli M, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P, et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med. 2015;373(11):997-1009. doi:10.1056/NEJMoa1507854 · PMID 26324049C5G2I1
  201. Valgimigli M, Gagnor A, Calabró P, Frigoli E, Leonardi S, Zaro T, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015;385(9986):2465-76. doi:10.1016/S0140-6736(15)60292-6 · PMID 25791214G2
  202. Valgimigli M, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, et al. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. N Engl J Med. 2021;385(18):1643-1655. doi:10.1056/NEJMoa2108749 · PMID 34449185G2
  203. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. doi:10.1093/eurheartj/ehae176 · PMID 39210723C4
  204. Van't Hof AWJ, Gibson CM, Rikken SAOF, Januzzi JL, Granger CB, van Beurden A, et al. Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction. NEJM Evid. 2026;5(1):EVIDoa2500268. doi:10.1056/EVIDoa2500268 · PMID 41211981G2
  205. Vora KP, Bhatt K, Doshi S, Poptani V, Kumar A, Finney R, et al. Intravenous dexrazoxane for haemorrhagic myocardial infarction: the SHIELD-MI study. Eur Heart J. 2026;pii: ehag715. doi: 10.1093/eurheartj/ehag715. doi:10.1093/eurheartj/ehag715 · PMID 42670881G2
  206. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-3537. doi:10.1093/eurheartj/ehae177 · PMID 39210710B4C8D1G1H3I1
  207. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57. doi:10.1056/NEJMoa0904327 · PMID 19717846C5G2I1
  208. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-48. doi:10.1056/NEJMoa043545 · PMID 16034009I1
  209. Watanabe H, Ozasa N, Morimoto T, Shiomi H, Bingyuan B, Suwa S, et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS One. 2018;13(8):e0199347. doi:10.1371/journal.pone.0199347 · PMID 30153268G2I1
  210. Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, et al. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiol. 2022;7(4):407-417. doi:10.1001/jamacardio.2021.5244 · PMID 35234821G2
  211. Williams MGL, Liang K, De Garate E, Spagnoli L, Fiori E, Dastidar A, et al. Peak Troponin and CMR to Guide Management in Suspected ACS and Nonobstructive Coronary Arteries. JACC Cardiovasc Imaging. 2022;15(9):1578-1587. doi:10.1016/j.jcmg.2022.03.017 · PMID 36075617H3
  212. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. doi:10.1056/NEJMoa0706482 · PMID 17982182C5G2I1
  213. Wood DA, Jennings CS, Kotseva K, Adamska A, Erlund I, Ganly S, et al. ESC Guidelines on prevention and rehabilitation in coronary heart disease and current practice: the EUROASPIRE VI survey. Eur Heart J. 2026;pii: ehag741. doi: 10.1093/eurheartj/ehag741. doi:10.1093/eurheartj/ehag741 · PMID 42666091G3H2
  214. Yndigegn T, Lindahl B, Mars K, Alfredsson J, Benatar J, Brandin L, et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024;390(15):1372-1381. doi:10.1056/NEJMoa2401479 · PMID 38587241G2H4I1
  215. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502. doi:10.1056/NEJMoa010746 · PMID 11519503G2I1
  216. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295(13):1519-30. doi:10.1001/jama.295.13.joc60038 · PMID 16537725C5G2I1
  217. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. doi:10.1056/NEJMoa1009492 · PMID 21073363I1
  218. Zeymer U, Ludman P, Danchin N, Kala P, Laroche C, Sadeghi M, et al. Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology. Eur Heart J. 2021;42(44):4536-4549. doi:10.1093/eurheartj/ehab342 · PMID 34389857G3
  219. Zeymer U, Goss F, Kunadt M, Oldenburg S, Hochadel M, Thiele H, et al. Patient knowledge about risk factors, achievement of target values, and guideline-adherent secondary prevention therapies 12 months after acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2024;13(7):537-545. doi:10.1093/ehjacc/zuae066 · PMID 38768234C8

Otros documentos con DOI (3)

  1. Comentarios a la guía ESC 2023 sobre el diagnóstico y tratamiento de los síndromes coronarios agudos. Revista Española de Cardiología. 2024;77(3):201-205. doi:10.1016/j.recesp.2023.11.007G1
  2. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. The Lancet. 1999;353(9146):9-13. doi:10.1016/S0140-6736(98)11181-9I1
  3. THEACUTEINFARCTIONRAMIPRILEFFI. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Lancet. 1993;342(8875). doi:10.1016/0140-6736(93)92693-NI1

Fichas técnicas (CIMA, AEMPS) (40)

  1. Ficha técnica de acetilsalicilato de lisina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 51209C3
  2. Ficha técnica de alirocumab. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 1151031008I1
  3. Ficha técnica de apixabán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 111691009C4
  4. Ficha técnica de atorvastatina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 61716I1
  5. Ficha técnica de bisoprolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 57655I1
  6. Ficha técnica de bisoprolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 70741I1
  7. Ficha técnica de bivalirudina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 80912C3C5I1I2
  8. Ficha técnica de cangrelor. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 115994001C1C3C4I1I2
  9. Ficha técnica de carvedilol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 59695I1
  10. Ficha técnica de clopidogrel. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 98069009C3
  11. Ficha técnica de clopidogrel. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 98070001C1C3C4C5D4I1I2
  12. Ficha técnica de colchicina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 78947I1
  13. Ficha técnica de dabigatrán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 08442011C3C4
  14. Ficha técnica de edoxabán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 115993018C4
  15. Ficha técnica de enoxaparina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 62472C3C5I1I2
  16. Ficha técnica de eplerenona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 66356I1
  17. Ficha técnica de evolocumab. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 1151016002I1
  18. Ficha técnica de ezetimiba. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 65376I1
  19. Ficha técnica de fondaparinux. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 02206003C3C5I1I2
  20. Ficha técnica de heparina sódica. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 56465C3C5I1I2
  21. Ficha técnica de icosapento de etilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 1201524001I1
  22. Ficha técnica de inclisirán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 1201494001I1
  23. Ficha técnica de lisinopril. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 59127I1
  24. Ficha técnica de metoprolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 56989I1
  25. Ficha técnica de metoprolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 82000I1
  26. Ficha técnica de nitroglicerina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 57127I1
  27. Ficha técnica de prasugrel. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 08503002C3
  28. Ficha técnica de prasugrel. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 08503009C1C3C4C5D4I1I2
  29. Ficha técnica de ramipril. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 59564I1
  30. Ficha técnica de rivaroxabán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 08472018C3C4
  31. Ficha técnica de rivaroxabán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 108472027C3
  32. Ficha técnica de rosuvastatina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 70243I1
  33. Ficha técnica de ticagrelor. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 10655004C1D4
  34. Ficha técnica de ticagrelor. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 110655009C3C4C5I1I2
  35. Ficha técnica de tirofibán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 62713C3
  36. Ficha técnica de valsartán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 70323I1
  37. Ficha técnica de ácido acetilsalicílico. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 42991C3D4
  38. Ficha técnica de ácido acetilsalicílico. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 81216C3C4I1I2
  39. Ficha técnica de ácido bempedoico. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 1201425002I1
  40. Ficha técnica de ácido bempedoico y ezetimiba. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 28/10/2026. CIMA, registro 1201424002I1
La lista se hace sola con lo que citan las páginas de este ESPACIO (PubMed por el PMID; el DOI, en PubMed o en Crossref; las fichas técnicas, en CIMA; los estudios en marcha, en ClinicalTrials.gov) y se rehace cada vez que se actualiza el ESPACIO; seis autores y «et al.», como pide el estilo Vancouver.

Actualidad

Formación

CardioTeca

Legal

La información que figura en CardioTeca.com está dirigida exclusivamente al profesional sanitario facultado para prescribir o dispensar medicamentos, por lo que se requiere una formación especializada para su correcta interpretación. El acceso a algunas secciones se realiza mediante contraseña, y sólo está disponible para profesionales sanitarios. Aunque el sitio web CardioTeca.com está dirigido a profesionales de la salud, la información médica visible en su área pública es de libre acceso. Por ello, queremos aclarar que el uso de estos contenidos por parte de la población no reemplaza en ningún momento la relación entre el médico y el paciente. Para obtener información específica sobre un caso concreto consulte siempre a su médico. En CardioTeca.com empleamos inteligencia artificial como herramienta de apoyo editorial, bajo supervisión de nuestro equipo médico.